KCM Investment Advisors LLC Sells 3,265 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

KCM Investment Advisors LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,592 shares of the medical research company’s stock after selling 3,265 shares during the period. KCM Investment Advisors LLC’s holdings in Thermo Fisher Scientific were worth $3,429,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Resona Asset Management Co. Ltd. acquired a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $57,107,000. Riverwater Partners LLC raised its position in shares of Thermo Fisher Scientific by 5.3% during the fourth quarter. Riverwater Partners LLC now owns 1,812 shares of the medical research company’s stock worth $943,000 after purchasing an additional 91 shares during the period. Prudential PLC lifted its holdings in shares of Thermo Fisher Scientific by 1.3% in the 4th quarter. Prudential PLC now owns 6,821 shares of the medical research company’s stock worth $3,548,000 after purchasing an additional 86 shares in the last quarter. Landscape Capital Management L.L.C. increased its stake in Thermo Fisher Scientific by 292.1% during the 4th quarter. Landscape Capital Management L.L.C. now owns 1,490 shares of the medical research company’s stock valued at $775,000 after purchasing an additional 1,110 shares in the last quarter. Finally, Magellan Asset Management Ltd acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $3,002,000. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 9,825 shares of the stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares in the company, valued at approximately $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares of the company’s stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 23,900 shares of company stock valued at $13,106,062. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

TMO opened at $437.71 on Friday. The firm has a 50-day moving average price of $532.01 and a 200-day moving average price of $547.47. Thermo Fisher Scientific Inc. has a twelve month low of $437.22 and a twelve month high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $165.13 billion, a price-to-earnings ratio of 26.48, a PEG ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a dividend yield of 0.39%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.41%.

Wall Street Analyst Weigh In

Several research firms have recently commented on TMO. Wells Fargo & Company boosted their target price on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. Morgan Stanley raised their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a report on Friday, January 10th. Royal Bank of Canada set a $693.00 price objective on shares of Thermo Fisher Scientific in a report on Friday, January 31st. Finally, Bank of America lowered their target price on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating for the company in a report on Friday, December 13th. Four analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $653.23.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.